Non-surgical treatment options for pulmonary aspergilloma.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
04 2020
Historique:
received: 07 10 2019
accepted: 17 02 2020
entrez: 29 3 2020
pubmed: 29 3 2020
medline: 22 10 2020
Statut: ppublish

Résumé

Aspergilloma, also known as mycetoma or fungus ball, is the most common manifestation of pulmonary involvement by Aspergillus species. The fungal ball typically forms within preexisting cavities of the lungs. Diagnosis requires both radiographic evidence along with serologic or microbiologic evidence of Aspergillus species involvement. While clinical features such as hemoptysis, chest pain, shortness of breath, cough, and fever are helpful in diagnosis, they are non-specific symptoms. Surgery is currently the mainstay of treatment for aspergilloma but is associated with considerable mortality and morbidity. Alternative options exist for patients who are poor surgical candidates and for those who prefer a less invasive treatment modality. Systemic treatment with amphotericin B is ineffective and is not recommended as a monotherapy, but systemic azoles is effective in approximately 50-80% of patients. Potential alternatives to surgery include intracavitary instillation or endobronchial administration of antifungal medication, as well as direct transbronchial aspergilloma removal. Bronchial artery embolization and radiotherapy are options to manage hemoptysis until definite eradication of the aspergilloma. More rigorous studies are needed to better establish non-surgical treatment paradigm for inoperable patients.

Identifiants

pubmed: 32217289
pii: S0954-6111(20)30043-3
doi: 10.1016/j.rmed.2020.105903
pii:
doi:

Substances chimiques

Antifungal Agents 0
Azoles 0
Amphotericin B 7XU7A7DROE

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105903

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Min Lang (M)

Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: mlang@mgh.harvard.edu.

Angela L Lang (AL)

Department of Anesthesia, Critcal Care, and Pain Management, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Nikunj Chauhan (N)

Department of Interventional Radiology, Cleveland Clinic Foundation, Cleveland, OH, USA.

Amanjit Gill (A)

Department of Interventional Radiology, Cleveland Clinic Foundation, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH